Offidani M, Corvatta L. Elotuzumab: the first available immunotherapeutic arrow against relapsed-refractory Multiple Myeloma. Eur J Oncol Env Hea [Internet]. 2017 Nov. 17 [cited 2025 Jan. 25];22(2):65-70. Available from: https://mail.mattioli1885journals.com/index.php/EJOEH/article/view/6857